Biased Evaluation in Cancer Drug Trials—How Use of Progression-Free Survival as the Primary End Point Can Mislead
Ian F. Tannock, Gregory R. Pond, Christopher M. Booth
Abstract
This Viewpoint discusses whether the use of progression-free survival as the primary end point in cancer drug trials can result in misleading interpretations of improved overall survival and quality of life.
Topics & Concepts
MedicineEnd pointClinical endpointEndpoint DeterminationCancerSurrogate endpointCancer drugsClinical trialQuality of life (healthcare)Progression-free survivalOverall survivalDrugOncologyIntensive care medicineInternal medicinePharmacologyGeometryNursingMathematicsAdvanced Breast Cancer TherapiesCancer Genomics and DiagnosticsCancer-related Molecular Pathways